Carriers of CALR Mutations at Decreased Risk for Thrombotic Events Among Patients With Essential Thrombocythemia
Researchers determined the impact of mutations in the CALR gene on thrombotic risk for patients with essential thrombocythemia.
Home
Guidance on Lifestyle Factors Provided at a Lower Rate to Cancer Survivors
Analysis of data from National Health Interview Survey reveals differences and similarities in counseling on diet, exercise, and smoking for cancer survivors and those with no cancer history.
Aspirin May Increase Bladder Cancer Survival
Investigators found no survival benefit among older patients with esophageal, gastric, pancreatic, or uterine cancer taking aspirin.
Tumor Genomic Subtype Might Influence Level of ctDNA Shedding in NSCLC
Investigators retrospectively analyzed circulating tumor DNA (ctDNA)-based and tissue-based genomic data from 144 patients with non-small cell lung cancer (NSCLC).
Study Data Suggest Role for Lenvatinib in Unresectable HCC With Child-Pugh B Liver Function
Outcomes of lenvatinib-receiving patients who progressed to Child-Pugh B liver function within the first 8 weeks of treatment were compared with those of patients who maintained Child-Pugh A classification during the same time period.
Zanidatamab Active in HER2-Positive Biliary Tract Cancer
Bernstam et al presented findings from an expansion cohort of a phase 1 trial testing the bispecific HER2-targeted antibody zanidatamab in patients with HER2-overexpressing biliary tract cancer.
In NSCLC, Many Small Cell Transformations Could Be Pseudo Transformations
This retrospective study reviewed small cell transformation (SCT) cases from the past 2 years to investigate the phenomenon of pseudo-SCT.
Facebook Group Pages Still a Source of Potentially Harmful Cancer Therapy Misinformation
Although the social media platform has cleaned up its content, this investigation shows clinicians still need to be aware of where their patients are getting information.
COBRA Study to Test ctDNA as Biomarker for Adjuvant Chemotherapy Benefit in Colon Cancer
COBRA investigators will evaluate circulating tumor DNA (ctDNA) as a biomarker for adjuvant chemotherapy benefit in 1408 patients with resected, stable stage IIA colon cancer.
Tivozanib and Durvalumab Doublet Regimen Is Well-Tolerated in HCC
Combination tivozanib and durvalumab was found to be well-tolerated in patients with advanced, treatment-naïve hepatocellular carcinoma (HCC).
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
Next post in Gastrointestinal Cancer
